Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)
-
Narrated by:
-
By:
About this listen
Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:
- Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
- Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
- Targeting TROP2 with ADCs (9:12)
- Targeting folate receptor alpha with ADCs (14:17)
- Targeting cadherin-6 with ADCs (17:27)
- Targeting HER2 with ADCs (26:12)
- Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)
CME information and select publications
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.